drugset / Trial / NCT00129532
Trial of SAVVY and HIV in Ghana
Phase 3
Unknown
2142 enrolled
Biosyn
FHI 360 · collabUnited States Agency for International Development (USAID) · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.
Timeline
- Start
- 2004-01
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C31G | Unknown | 1 % | Other |